Vascular Impact of Cancer Therapies: The Case ... - CLL Support
Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors
You need to be a member of this community to see this post.
Read more about...
7 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
Novel Bruton’s Tyrosine Kinase (BTK) inhibitor, ONO-4059 enters UK CLL clinical trial
trials landscape is fast changing as many novel targeted therapies enter UK trials:
UK Trials...
Attention Those Taking Ibrutinib & BTK Inhibitors:Second Cancer Incidence in CLL Patients Receiving BTK Inhibitors
between the use of ibrutinib and acalabrutinib with the incidence of second primary cancers.
There...
Ibrutinib Slow but steady foreward movement.
called Bruton's tyrosine kinase (BTK) inhibitors. Data suggest ibrutinib covalently bonds to BTK in...
Second-Generation BTK Inhibitors Hit the Treatment Bullseye With Fewer Off-Target Effects
com/view/second-generation-btk-inhibitors-hit-the-treatment-bullseye-with-fewer-off-target-effects...
A Conversation with Dr Tam about Zanubrutinib: A Novel BTK Inhibitor
from ibrutinib in pharmacokinetics and target occupancy?
Zanubrutinib has a more-specific target...
CALQUENCE gets FDA approval for treating CLL
The possible efficacy of BTK inhibitors lessening the effects of COVID-19
EHA 2022: Outcomes Following Treatment With a Covalent BTK and BCL2 Inhibitor
A new kid on the block? Nemtabrutinib
